NTRK2 and glioma: Local delivery of the TrkB antagonist decreased glioma cell proliferation in the midbrain (Figure 3H), though not to baseline levels, highlighting both the contribution of BDNF-TrkB signaling in cholinergic neuronal activity-dependent DMG growth in the midbrain and the existence of multiple activity-regulated mechanisms.